MOAI Consulting developed the AMPLIFY tool to estimate the clinical and humanistic benefits associated with pembrolizumab use across reimbursed indications in Portugal. Published in PharmacoEconomics – Open, the study estimated that, between 2017 and 2024, pembrolizumab treatment for 13,530 patients generated 14,042 additional quality-adjusted life years (QALYs), 17,914 additional life years, and 2,021 avoided deaths.
One-third of patients with depression do not show improvement with medication
Expresso published the results of the study “The Perspective of Patients with Depression in Portugal”, developed by FamiliarMente, the Portuguese Federation of Associations of Families of People with Mental Illness, and Johnson & Johnson Innovative Medicine, with technical support from MOAI Consulting.
Obesity will account for 20% of the State Budget for healthcare in 2025
MOAI conducted a study with support from Johnson & Johnson MedTech Portugal, highlight the economic and clinical dimensions of the obesity burden: direct treatment of the disease costs 1.9 billion euros annually, to which must be added another 1.5 billion in expenses related to associated conditions, such as diabetes, hypertension, and various types of cancer.
Health and economic gains from bariatric surgery in Portugal: an in-depth analysis using a Markov model
MOAI developed a Markov model to assess the long-term cost-effectiveness of bariatric surgery compared with conventional treatment in the Portuguese healthcare setting. Published in Health Economics Review, the study showed that bariatric surgery is cost-effective within 10 years, becomes cost-saving after 20 years, and provides an additional 7 quality-adjusted life years (QALYs) while reducing lifetime healthcare costs by €4,534 per patient.
